Reviewing Sierra Oncology Inc. (SRRA)’s and Nabriva Therapeutics plc (NASDAQ:NBRV)’s results

Sierra Oncology Inc. (NASDAQ:SRRA) and Nabriva Therapeutics plc (NASDAQ:NBRV), both competing one another are Biotechnology companies. We will contrast their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sierra Oncology Inc. N/A -0.01 60.55M -0.74 0.00
Nabriva Therapeutics plc 2 -0.02 64.83M -2.10 0.00

Demonstrates Sierra Oncology Inc. and Nabriva Therapeutics plc earnings per share, gross revenue and valuation.

Profitability

Table 2 shows Sierra Oncology Inc. and Nabriva Therapeutics plc’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Sierra Oncology Inc. 20,469,912,102.77% -54.1% -48.3%
Nabriva Therapeutics plc 3,334,190,495.78% -162.3% -117.6%

Risk & Volatility

Sierra Oncology Inc. is 21.00% more volatile than S&P 500 because the stock has a beta of 1.21. Nabriva Therapeutics plc has a 2.4 beta and it is 140.00% more volatile than S&P 500.

Liquidity

Sierra Oncology Inc.’s Current Ratio and Quick Ratio are 13.1 and 13.1 respectively. The Current Ratio and Quick Ratio of its competitor Nabriva Therapeutics plc are 5.6 and 5.6 respectively. Sierra Oncology Inc. therefore has a better chance of paying off short and long-term obligations compared to Nabriva Therapeutics plc.

Insider & Institutional Ownership

Roughly 66.4% of Sierra Oncology Inc. shares are owned by institutional investors while 49.6% of Nabriva Therapeutics plc are owned by institutional investors. 1.38% are Sierra Oncology Inc.’s share owned by insiders. Competitively, 0.61% are Nabriva Therapeutics plc’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sierra Oncology Inc. -3.46% -5.24% -61.95% -61.39% -80.76% -60.51%
Nabriva Therapeutics plc -0.21% -1.86% 9.45% 24.35% -11.71% 62.67%

For the past year Sierra Oncology Inc. had bearish trend while Nabriva Therapeutics plc had bullish trend.

Summary

On 7 of the 10 factors Sierra Oncology Inc. beats Nabriva Therapeutics plc.

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The companyÂ’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical studies for antibacterial activity against various gram-positive bacteria, gram-negative bacteria, and atypical bacteria, including multi-drug resistant strains. In addition, the company is developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial for the treatment of various gram-positive infections, including uncomplicated skin and skin structure infections. Nabriva Therapeutics plc was founded in 2006 and is based in Dublin, Ireland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.